Status:
RECRUITING
Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Collaborating Sponsors:
Weizmann Institute of Science
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
Current guidelines mandate Helicobacter pylori (H. Pylori) eradication with 2-3 antibiotics for 14 days ,This may result in multiple side effects and in eradication of important bacterial species to h...
Detailed Description
This is a pilot study. Prior to antibiotics therapy for their baseline H.Pylori infection, patients will be asked to deliver at least 50 grams of fresh stool to the Tel Aviv Medical Center (TLVMC) Bac...
Eligibility Criteria
Inclusion
- Age 18-70 years old
- Positive H. pylori on either breath test or gastric biopsy
- Patient is intended to receive antibiotics therapy for H. pylori eradication
Exclusion
- Severe systemic disease that may impact the microbiome. For example: heart disease, type two diabetes, chronic liver or kidney failure
- Antibiotics therapy during the prior 2 months to enrollment
- Planned to receive antibiotics within the upcoming 2 months (surgery etc) for reasons other than H. Pylori
- Inability to complete the study protocol (swallow capsules or to hold enema content for at least 15 minutes)
- Pregnancy
- Inability to give informed consent
Key Trial Info
Start Date :
September 26 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05329636
Start Date
September 26 2018
End Date
July 1 2026
Last Update
July 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dep. of Gastroenterology, Tel Aviv Sourasky Medical Center
Tel Aviv, Israel